Vir Biotechnology, Inc.

Powering the Immune System to Transform Lives

Founded 2016

San Francisco, United States 450 employees Total: $1.37B Biotechnology, Health Care +1

General Information

Company Name Vir Biotechnology, Inc.

Founded Year 2016

Location

San Francisco, United States

Employees 450

Industries Biotechnology, Health Care, Health and Wellness

Business Model B2B, B2B2C

Revenue Model Product Sales, Licensing, Value Based Pricing

Hiring 16 roles posted in the month to 5 Oct 2026

Offices as of Sep 2026

San Francisco, United States Bellinzona, Switzerland

Social

BounceWatch is an independent company data service, not affiliated with Vir Biotechnology, Inc.. To contact Vir Biotechnology, Inc., visit vir.bio.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vir Biotechnology, Inc. compare?

A PDF of Vir Biotechnology, Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vir Biotechnology, Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

New Partnership Oct 08, 2026

Vir Biotechnology, Inc. is collaborating with Astellas Pharma as a global strategic collaborator to rapidly advance VIR-5500, a potential innovative treatment option for mCRPC.

Key Hire Oct 07, 2026

Vir Biotechnology, Inc. announced the hire of David Liu, M.D., Ph.D., as their new Executive Vice President and Chief Medical Officer.

Event Participation Oct 05, 2026

Vir Biotechnology, Inc. is presenting expanded Phase 2 SOLSTICE results for elebsiran and tobevebart in chronic hepatitis delta at the American Association for the Study of Liver Diseases (AASLD) T…

In The News Oct 03, 2026

Featured on Yahoo! Finance Canada: Vir Biotechnology, Inc. (VIR) Stock Forecasts

Actively Hiring Oct 01, 2026

Hiring for 16 positions in the last 30 days.

Get alerts when Vir Biotechnology, Inc. shows new signals

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., founded in 2016 and headquartered in the United States, operates with the mission of "Powering the Immune System to Transform Lives." The company is rooted in the Biotechnology, Health Care, and Health and Wellness industries, focusing on innovative solutions for serious infectious diseases and cancer.

Vir Biotechnology’s core strength lies in its dual-platform approach comprising a next-generation antibody platform and a protease-releasable masking platform. These technologies enable the rapid development of advanced therapeutic candidates, primarily targeting chronic hepatitis delta and extending to promising oncology endeavors.

In its continued pursuit of breakthroughs, Vir Biotechnology recently secured a substantial $315.00M in Post IPO Equity investment, primarily backed by Astellas Pharma, in April of 2026. This investment underscores confidence in the company’s capacity to develop transformative medicines at scale.

Business keywords: Immunology, Infectious Diseases, Chronic Hepatitis Delta, Oncology, Therapeutic Antibodies, Protease-Releasable Masking Platform, Immune Programming, Pathogen-Host Interactions, Hepatitis B, Influenza A, HIV, Tuberculosis, Clinical Medicine, Technology Platforms

Services & Products

Antibody-based Medicine Development

Clinical Research and Trials

Regulatory Strategy and Compliance

Product Commercialization

Innovative Drug Pipeline

Target Customers

Patients with Infectious Diseases Patients with Cancer Healthcare Professionals Pharmaceutical Collaborators Research Institutions

Funding Rounds & Investors (12)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Round	Undisclosed	-		01 Sep 2026
Post-IPO Equity	$315.00M	1	Astellas Pharma	01 Apr 2026
Grant	$50.00M	1	US Biomedical Advanced Research and Development Authority	01 Oct 2023
Grant	$10.00M	1	Bill & Melinda Gates Foundation	01 May 2023
Grant	$55.00M	-		01 Oct 2022
Post-IPO Equity	Undisclosed	-		01 Nov 2020
Post-IPO Equity	$250.00M	1	GSK	01 Apr 2020
IPO	$143.00M	-		01 Oct 2019
Series B	$327.60M	3	Arch Venture Partners, Alta Partners +1	01 Jan 2019
Series A	$66.00M	-		01 Aug 2018

View All 12 Funding Rounds

Latest News

View All

Vir Biotechnology, Inc. (VIR) Stock Forecasts

Yahoo! Finance Canada Oct 03, 2026

Vir Biotechnology, Inc. Alternatives & Competitors

View All Alternatives

Vir Biotechnology, Inc. vs

X-Vax Technology

Pioneering the future of vaccines to conquer mucosal infections and protect millions globally.

Series A

Biotechnology, Health Care

Vir Biotechnology, Inc. vs

CytoDyn United States

CytoDyn’s purpose is to help enhance the lives of patients with life-threatening diseases.

Post-IPO Equity

21 employees

Biotechnology, Health and Wellness

Vir Biotechnology, Inc. vs

Osivax France

Pioneering A New Class of Universal Vaccines

Grant

53 employees

Biotechnology, Health Care

View all alternatives

FAQ About Vir Biotechnology, Inc.

Powering the Immune System to Transform Lives

Vir Biotechnology, Inc. was founded in 2016.

Vir Biotechnology, Inc. is headquartered in San Francisco, United States. As of Sep 2026, it also has offices in Bellinzona, Switzerland.

Vir Biotechnology, Inc. operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Immunology, Infectious Diseases, Chronic Hepatitis Delta and Oncology. Its customers include Patients with Infectious Diseases, Patients with Cancer and Healthcare Professionals.

Vir Biotechnology, Inc. has a B2B and B2B2C business model. Its revenue comes from Product Sales, Licensing and Value Based Pricing.

Vir Biotechnology, Inc. has approximately 450 employees.

Vir Biotechnology, Inc. has completed 12 funding rounds, raising a total of $1.37B.

Vir Biotechnology, Inc. offers: Antibody-based Medicine Development, Clinical Research and Trials, Regulatory Strategy and Compliance, Product Commercialization, Innovative Drug Pipeline.

Top alternatives and competitors to Vir Biotechnology, Inc. include X-Vax Technology, CytoDyn, Osivax, Polaris Biology, Novavax. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Vir Biotechnology, Inc. and X-Vax Technology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vir Biotechnology, Inc., https://bouncewatch.com/company/vir-biotechnology-inc, updated 7 October 2026. When citing, please name BounceWatch and link this page.

Vir Biotechnology, Inc.

General Information

Discover More

What changed at Vir Biotechnology, Inc. recently?

About Vir Biotechnology, Inc.

Services & Products

Target Customers

Funding Rounds & Investors (12)

Latest News

Vir Biotechnology, Inc. Alternatives & Competitors

FAQ About Vir Biotechnology, Inc.